Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17745
Country/Region: Nigeria
Year: 2016
Main Partner: Achieving Health Nigeria Initiative
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $358,767 Additional Pipeline Funding: $317,673

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $65,166
Care: Orphans and Vulnerable Children (HKID) $55,918
Care: TB/HIV (HVTB) $71,733
Care: Pediatric Care and Support (PDCS) $55,721
Laboratory Infrastructure (HLAB) $0
Testing: HIV Testing and Counseling (HVCT) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $108,760
Treatment: Pediatric Treatment (PDTX) $1,469
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 20
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 17
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 37,849
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 283
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 38,169
HTS_TST Service Delivery Point (Facility): Outpatient 2017 426
HTS_TST Service Delivery Point (Facility): Pediatric 2017 37
HTS_TST Service Delivery Point (Facility): PMTCT 2017 37,530
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 18
HTS_TST Service Delivery Point (Facility): VCT 2017 158
HTS_TST Sum of Aggregated Age/Sex <15 2017 37
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 38,132
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 38,169
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 441
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 6
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 7
LAB_PT CD4: Number of laboratories that perform this testing 2017 7
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 6
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 7
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 7
OVC_SERV Age/Sex: 18+ Female 2017 70
OVC_SERV Age/Sex: 18+ Male 2017 71
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 638
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 638
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 1,417
OVC_SERV Sum of Age/Sex disaggregates 2017 141
PMTCT_ART Already on ART at beginning of current pregnancy 2017 159
PMTCT_ART New on ART 2017 587
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 37,525
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 563
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 189
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 6
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 19
PMTCT_EID Sum of Infant Age disaggregates 2017 752
PMTCT_STAT By: Known positives at entry 2017 314
PMTCT_STAT By: Number of new positives identified 2017 440
PMTCT_STAT Number of new ANC and L&D clients 2017 39,504
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 37,525
PMTCT_STAT Sum of Positives Status disaggregates 2017 754
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 8
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 7
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 17
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 15
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 49
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 45
TB_SCREENDX Screen Result: Screened Positive for TB 2017 53
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 1,668
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 592
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 49
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 50
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 2,359
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 30
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 54
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 87
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 97
TX_CURR Aggregated Age/Sex: <15 Female 2017 2
TX_CURR Aggregated Age/Sex: <15 Male 2017 8
TX_CURR Aggregated Age/Sex: 15+ Female 2017 1,094
TX_CURR Aggregated Age/Sex: 15+ Male 2017 401
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 1,505
TX_CURR Sum of Aggregated Age/Sex <15 2017 10
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 1,495
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 1,505
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 14
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 11
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 102
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 91
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 218
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 218
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 1,604
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 1,358
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 34
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 35
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 941
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 348
TX_PVLS Numerator: Indication: Routine 2017 1,085
TX_PVLS Numerator: Indication: Targeted 2017 272
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 35
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 38
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 1,120
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 411
TX_PVLS_den Denominator: Indication: Routine 2017 1,283
TX_PVLS_den Denominator: Indication: Targeted 2017 321
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 43
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 13
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 57
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 67
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 50
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 16
Cross Cutting Budget Categories and Known Amounts Total: $219,971
Human Resources for Health $50,450
Gender: Gender Based Violence (GBV) $9,411
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $145,110
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Motor Vehicles: Leased $15,000